aibio.space Distress & Restructuring Desk
Going-concern warnings, bankruptcies, restructurings, wind-downs, workforce cuts, late filings, defaults and forbearance.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 285 stories so far.
Latest stories
- Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts
- Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones
- LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%
- Artiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives
- Sangamo ends July in Chapter 11 with $16,906,955 in cash
- Supernus ends its UBS credit line ahead of the Indivior merger
- Fractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing
- EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss
- Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license
- Fractyl shares fall 48% even as Revita meets six-month REMAIN-1 endpoint
- Liquidia to pay net $175 million in global settlement with United Therapeutics
- Premier Air Charter says lessors terminated its CJ3 aircraft leases
- Caribou explores strategic alternatives and ends its allogeneic CAR-T programs
- Petros Pharmaceuticals assigns all assets to creditors and halts operations
- Lunai Bioworks delays annual report, expects net loss of about $3.2 million
- Advanced Biomed files late notice for annual report as audit is not complete
- Zeo ScientifiX says it cannot file its eight-month transition report on time
- America Great Health says it cannot file its annual report by September 30, 2026
- Adagio Medical starts strategic review and cuts workforce
- Xenon pauses depression trial enrollment after psychosis reports, shares drop
- Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029
- Evommune drops EVO756 in atopic dermatitis after phase 2b misses all endpoints
- TScan cuts 75% of staff and pauses phase 3 trial for lack of capital
- Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale
- BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder
- PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy
- PDS Biotechnology to cut about 36% of workforce, removes Chief Operating Officer
- Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover
- Curanex flags going-concern doubt with $2.94 million in cash at June 30
- Silexion had $2.2 million in cash at June 30 and flags going-concern doubt
- Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report
- ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report
- Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly
- Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt
- Pelthos Therapeutics says first-quarter 2026 financials can no longer be relied on, will restate
- Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report
- PTC named winning bidder for Sangamo's Fabry gene therapy ST-920
- Turn Therapeutics ends June with $10.3 million and a going-concern warning
- Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029
- Anavex Life Sciences files NT 10-Q, says June quarter report is late amid special committee review
aibio